George J. Cullinan

Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats.

Larry J. Black, Masahiko Sato, Ellen R. Rowley et al. · Journal of Clinical Investigation · 1994 · 612 citations · Full text

Lipid Peroxidation, Gynecology, Pharmacotherapy +20

Molecular determinants of tissue selectivity in estrogen receptor modulators

Timothy A. Grese, James P. Sluka, Henry U. Bryant et al. · Proceedings of the National Academy of Sciences · 1997 · 242 citations · Full text

Estrogen Receptor, Gynecology, Raloxifene Analogs +16

LY320135, a Novel Cannabinoid CB1 Receptor Antagonist, Unmasks Coupling of the CB1 Receptor to Stimulation of cAMP Accumulation

Christian C. Felder, Kelly E. Joyce, Eileen M. Briley et al. · Journal of Pharmacology and Experimental Therapeutics · 1998 · 231 citations

Discovery and Synthesis of [6-Hydroxy-3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]- 2-(4-hydroxyphenyl)]benzo[<i>b</i>]thiophene:  A Novel, Highly Potent, Selective Estrogen Receptor Modulator

Alan D. Palkowitz, Andrew L. Glasebrook, K. Jeff Thrasher et al. · Journal of Medicinal Chemistry · 1997 · 176 citations

Structure-activity relationships of dimeric Catharanthus alkaloids. 1. Deacetyl vinblastine amide (vindesine) sulfate

Charles J. Barnett, George J. Cullinan, Koert Gerzon et al. · Journal of Medicinal Chemistry · 1978 · 138 citations